Tenax Therapeutics (TENX) Other Non-Current Assets (2011 - 2024)
Tenax Therapeutics (TENX) posted quarterly Other Non-Current Assets of $1117.0 for Q3 2024, little changed year-over-year from $1117.0 in Q4 2023, and little changed on a QoQ basis from $1117.0 in Q2 2024.
Tenax Therapeutics (TENX) Other Non-Current Assets (2011 - 2024) Analysis & Trends
Tenax Therapeutics has reported Other Non-Current Assets for 13 years, with the latest figure at $1117.0 in Q3 2024.
- Other Non-Current Assets for Q3 2024 came in at $1117.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2024 was $1117.0 (changed 0.0% YoY), and the FY2023 annual result was $1000.0, down 89.53% from the prior year.
- Other Non-Current Assets steadied at $1117.0 in Q3 2024, from $1117.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $9552.0 in Q4 2022 and troughed at $1000.0 in Q4 2023.
- A 5-year average of $5791.5 and a median of $8435.0 in 2020 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2022, when Other Non-Current Assets advanced 13.24%; it then plunged 89.53% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $8435.0 in 2020, then changed by 0.0% to $8435.0 in 2021, then climbed by 13.24% to $9552.0 in 2022, then plunged by 89.53% to $1000.0 in 2023, then increased by 11.7% to $1117.0 in 2024.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $1117.0 in Q3 2024, $1117.0 in Q2 2024, and $1117.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1,117.00 |
| Jun 30, 2024 | 1,117.00 |
| Mar 31, 2024 | 1,117.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,117.00 |
| Jun 30, 2023 | 1,117.00 |
| Mar 31, 2023 | 1,117.00 |
| Dec 31, 2022 | 9,552.00 |
| Sep 30, 2022 | 8,435.00 |
| Jun 30, 2022 | 8,435.00 |
| Mar 31, 2022 | 8,435.00 |
| Dec 31, 2021 | 8,435.00 |
| Sep 30, 2021 | 8,435.00 |
| Jun 30, 2021 | 8,435.00 |
| Mar 31, 2021 | 8,435.00 |
| Dec 31, 2020 | 8,435.00 |
| Sep 30, 2020 | 8,435.00 |
| Jun 30, 2020 | 8,435.00 |
| Mar 31, 2020 | 8,435.00 |
| Dec 31, 2019 | 8,435.00 |